Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Option and Sells Shares
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold a portion of the acquired shares on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 1,400 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 1,400 shares of common stock at a weighted average price of $10.0021 per share, with prices ranging from $10.00 to $10.02.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and holds options for 43,600 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive under a pre-existing plan. It doesn't inherently indicate positive or negative news about the company.
Industry Context
Executive stock transactions are common and closely monitored, especially in publicly traded companies like Amicus Therapeutics. Rule 10b5-1 plans are frequently used to allow insiders to trade company stock without concerns about insider trading violations.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings while avoiding potential insider trading accusations.
- Comparing Campbell's stock transactions to those of executives at similar biotech companies (e.g., BioMarin, Vertex) would provide context on the scale and frequency of such activities.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares traded.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| August 23, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| January 2, 2025 | Expiration date of stock options |
| July 1, 2024 | Date of stock option exercise and sale of shares |
| July 3, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.